AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24298766 — intervention group
Group type: COMPARATOR
Intervention: Medication (loratadine tablet and azelastine hydrochloride nasal spray)
Number of subjects: 81
Study 20716757 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 436
Study 20716757 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 436
Study 20716757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 436
Study 20716757 — intervention group
Group type: COMPARATOR
Intervention: No tirofiban
Number of subjects: 436
Study 18165210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 29
Study 18165210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine ophthalmic solution 0.4%
Number of subjects: 29
Study 18165210 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 0.09%
Number of subjects: 29
Study 15752391 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cessation of sevoflurane
Number of subjects: 85
Study 15752391 — intervention group
Group type: COMPARATOR
Intervention: Gradual decrease of sevoflurane (0.1% min(-1))
Number of subjects: 85
Study 12095313 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-adenovirus (VEGF-Ad) - 2x10(10) plaque-forming units (pfu)
Number of subjects: 54
Study 12095313 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-plasmid/liposome (VEGF-P/L) - 2000 microg of VEGF plasmid, 2000 microl of DOTMA:DOPE
Number of subjects: 54
Study 12095313 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (control)
Number of subjects: 54
Study 10376228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative education
Number of subjects: 0
Study 10376228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-operative education)
Number of subjects: 0
Study 7484890 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 800
Study 7484890 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 800
Study 2272044 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC every 3 weeks
Number of subjects: 99
Study 2272044 — intervention group
Group type: COMPARATOR
Intervention: LMF (leukeran, methotrexate, 5‐fluorouracil) every 6 weeks
Number of subjects: 99
Study 2272044 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (5‐fluorouracil, 4‐epirubicin, cyclophosphamide)
Number of subjects: 99
Study 7032640 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (50 mg in 50 ml of saline for 30 min)
Number of subjects: 60
Study 7032640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study 31855162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 861
Study 28028192 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 9270
Study 28028192 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 9270
Study 25833777 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI-LF breakfast (high glycemic index, low fiber)
Number of subjects: 14
Study 25833777 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI-LF breakfast
Number of subjects: 14
Study 25833777 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI-LF breakfast
Number of subjects: 14
Study 25833777 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI-HF and LGI-LF breakfasts
Number of subjects: 14
Study 23512156 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN) for circumferential pulmonary vein ablation (PVA)
Number of subjects: 138
Study 21800045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheet listing two causes of colon cancer (polyps and cause unknown) and six ways to help prevent colon cancer (lifestyle, diet, weight, smoking, alcohol, and screening)
Number of subjects: 66
Study 21800045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheet intervention
Number of subjects: 66
Study 19682173 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk drink (once a day for 8 weeks)
Number of subjects: 50
Study 19682173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no product to drink)
Number of subjects: 50
Study 17966758 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide 250 mg tablet (test formulation)
Number of subjects: 36
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lisinopril
Number of subjects: 30
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 20 mg olmesartan medoxomil
Number of subjects: 30
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 40 mg olmesartan medoxomil
Number of subjects: 30
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 80 mg olmesartan medoxomil
Number of subjects: 30
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lisinopril plus 20 mg olmesartan medoxomil
Number of subjects: 30
Study 16321616 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lisinopril plus 40 mg olmesartan medoxomil
Number of subjects: 30
Study 11912111 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger tracking training (18-20 sessions)
Number of subjects: 10
Study 11912111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment during control period)
Number of subjects: 10
Study 11912111 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger tracking training
Number of subjects: 10
Study 9797755 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled LPS (60 micrograms)
Number of subjects: 26
Study 9797755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 26
Study 7648773 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine maleate 150 mg/day
Number of subjects: 449
Study 7648773 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine maleate 225 mg/day
Number of subjects: 449
Study 7648773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 2705425 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person interviews
Number of subjects: 342
Study 2705425 — intervention group
Group type: COMPARATOR
Intervention: Mail approaches
Number of subjects: 342
Study 2705425 — intervention group
Group type: COMPARATOR
Intervention: Mail methodologies
Number of subjects: 342
Study 792477 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 202
Study 792477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 30843501 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU daily vitamin D3 supplementation
Number of subjects: 1008
Study 30843501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU daily vitamin D3 supplementation
Number of subjects: 1008
Study 30843501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU daily vitamin D3 supplementation
Number of subjects: 1008
Study 30843501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1008
Study 29356445 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to weather-related stressors (30 min of a 3°C decrease in temperature, simulated rain, or 2 hr of food removal, 4 times daily for 3 weeks)
Number of subjects: 0
Study 29356445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the absence of the experimental stressors)
Number of subjects: 0
Study 25809925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (G1)
Number of subjects: 85
Study 25809925 — intervention group
Group type: EXPERIMENTAL
Intervention: PFME combined with anal electrical stimulation (G2)
Number of subjects: 85
Study 25809925 — intervention group
Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 85
Study 25128510 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise intervention
Number of subjects: 78
Study 25128510 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study 21626613 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group psychotherapy
Number of subjects: 0
Study 21626613 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic group psychotherapy
Number of subjects: 0
Study 21626613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both short-term and long-term psychodynamic group psychotherapy
Number of subjects: 0
Study 19671655 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 36 months
Number of subjects: 7868
Study 19671655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7868
Study 17184430 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body warming (UBW)
Number of subjects: 73
Study 17184430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body warming (LBW)
Number of subjects: 73
Study 16280694 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus optimized background regimen (OB)
Number of subjects: 995
Study 16280694 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimized background regimen only)
Number of subjects: 995
Study 12160199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (continued)
Number of subjects: 23
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score > or = 6
Number of subjects: 128
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length < or = 26 mm
Number of subjects: 128
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive FNf assay
Number of subjects: 128
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin assay
Number of subjects: 128
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score
Number of subjects: 128
Study 10437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 128
Study 8846489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25)
Number of subjects: 3673
Study 8846489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg/kg (M15)
Number of subjects: 3673
Study 8846489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25) split dose
Number of subjects: 3673
Study 8846489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25) with artesunate on the second day
Number of subjects: 3673
Study 2210983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injections combined with internal urethrotomy
Number of subjects: 38
Study 2210983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injections
Number of subjects: 38
Study 2210983 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy
Number of subjects: 38
Study 434434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (4 ml)
Number of subjects: 0
Study 434434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% (4 ml)
Number of subjects: 0
Study 31927404 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavior Program
Number of subjects: 58
Study 31927404 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 58
Study 30144462 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation (10 min at 1.5 mA) over the left DLPFC at Fp3
Number of subjects: 144
Study 30144462 — intervention group
Group type: COMPARATOR
Intervention: Active control (different tDCS targeted brain area)
Number of subjects: 144
Study 26834462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (3, 6, or 9 mg/day)
Number of subjects: 38
Study 24842200 — intervention group
Group type: EXPERIMENTAL
Intervention: HES-Group (Colloid Prime)
Number of subjects: 40
Study 24842200 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid Group (Ringer's Lactate)
Number of subjects: 40
Study 24842200 — intervention group
Group type: EXPERIMENTAL
Intervention: HES-Group
Number of subjects: 40
Study 24842200 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid Group
Number of subjects: 40
Study 24842200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 40
Study 22882724 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once-daily for 12 weeks
Number of subjects: 501
Study 22882724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 20661103 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 + 1 regimen (PCV7 at 2, 4, 6, and 12 months)
Number of subjects: 543
Study 20661103 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 + 1 regimen (PCV7 at 4, 6, and 12 months)
Number of subjects: 543
Study 20661103 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 + 0 regimen (PCV7 at 2, 4, and 6 months)
Number of subjects: 543
Study 18365859 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) for 12 weeks
Number of subjects: 45
Study 18365859 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) for 24 months
Number of subjects: 45
Study 15997446 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal surgery
Number of subjects: 347
Study 15997446 — intervention group
Group type: COMPARATOR
Intervention: Open rectal surgery
Number of subjects: 347
Study 15997446 — intervention group
Group type: COMPARATOR
Intervention: Female sexual function
Number of subjects: 347
Study 15131517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 20
Study 10573241 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 53
Study 10573241 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 53
Study 8920706 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV vaccine (10^4 p.f.u.)
Number of subjects: 800
Study 8920706 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype G2 vaccine
Number of subjects: 800
Study 8920706 — intervention group
Group type: COMPARATOR
Intervention: Serotype G1 or G2 vaccines
Number of subjects: 800
Study 1864291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (enoxacin, ofloxacin, pefloxacin, ciprofloxacin)
Number of subjects: 0
Study 1864291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0
Study 1864291 — intervention group
Group type: EXPERIMENTAL
Intervention: New quinolones
Number of subjects: 0
Study 1864291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones with or without erythromycin and rifampin
Number of subjects: 0
Study 1864291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones
Number of subjects: 0
Study 6836636 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (18 to 21 Gy for one week)
Number of subjects: 60
Study 6836636 — intervention group
Group type: COMPARATOR
Intervention: Nephrectomy and postoperative radiation (no preoperative radiation)
Number of subjects: 60
Study 31053082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index (HPI) software guidance
Number of subjects: 213
Study 31053082 — intervention group
Group type: COMPARATOR
Intervention: Blinded monitoring
Number of subjects: 213
Study 31053082 — intervention group
Group type: COMPARATOR
Intervention: Unblinded monitoring
Number of subjects: 213
Study 29870325 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + Education Program and Active Outpatient Monitoring (OMT + A)
Number of subjects: 237
Study 29870325 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medicine Treatment (OMT)
Number of subjects: 237
Study 29870325 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + Additional Exposure (DV)
Number of subjects: 237
Study 29870325 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + DV
Number of subjects: 237
Study 27919453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group (daily replacement of a portion of staple food with TB food)
Number of subjects: 165
Study 27919453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group
Number of subjects: 165
Study 27919453 — intervention group
Group type: COMPARATOR
Intervention: Control diet group (DC group; systematic diet plans and intensive nutritional education)
Number of subjects: 165
Study 27919453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group (greater than 110 g/d)
Number of subjects: 165
Study 24213956 — intervention group
Group type: EXPERIMENTAL
Intervention: MT + MG
Number of subjects: 43
Study 24213956 — intervention group
Group type: EXPERIMENTAL
Intervention: MT
Number of subjects: 43
Study 24213956 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 43
Study 22316357 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% discount on fruits and vegetables (experimental condition)
Number of subjects: 115
Study 22316357 — intervention group
Group type: COMPARATOR
Intervention: Regular prices (control condition)
Number of subjects: 115
Study 19577442 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy
Number of subjects: 0
Study 19577442 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 0
Study 19577442 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 17984375 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate (40 g, 70% cocoa)
Number of subjects: 22
Study 17984375 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate
Number of subjects: 22
Study 17984375 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-free control chocolate
Number of subjects: 22
Study 15964131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterocolposacropexy (HSP)
Number of subjects: 72
Study 15964131 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy followed by sacropexy (CSP)
Number of subjects: 72
Study 12032406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive altitude training (3100 m for 6 days)
Number of subjects: 9
Study 12032406 — intervention group
Group type: COMPARATOR
Intervention: Control (no regular physical activity)
Number of subjects: 9
Study 12032406 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude training effect on nitrite/nitrate levels
Number of subjects: 9
Study 9719328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 23
Study 9719328 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty (CA)
Number of subjects: 23
Study 7695416 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion of suctioned blood (n = 19)
Number of subjects: 40
Study 7695416 — intervention group
Group type: COMPARATOR
Intervention: Retainment of suctioned blood (n = 21)
Number of subjects: 40
Study 2973471 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH) infusion (0.75 pmol/kg.min)
Number of subjects: 6
Study 2973471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31112230 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Adiponectin (APN) levels
Number of subjects: 3361
Study 30307347 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based training (Arm 2)
Number of subjects: 204
Study 30307347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of scenario-based and conventional training (Arm 3)
Number of subjects: 204
Study 30307347 — intervention group
Group type: COMPARATOR
Intervention: Conventional asthma training (Arm 1)
Number of subjects: 204
Study 30307347 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 204
Study 28162145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy using a mobile application (CBT‐I‐MA)
Number of subjects: 19
Study 25752995 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement strategies including convening a Community Engagement Studio, redesigning recruitment advertisement, simplifying language, providing transportation
Number of subjects: 0
Study 23319696 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG plus DNX
Number of subjects: 394
Study 23319696 — intervention group
Group type: COMPARATOR
Intervention: FLAG
Number of subjects: 394
Study 16488056 — intervention group
Group type: EXPERIMENTAL
Intervention: Same Snack condition (crumb cake)
Number of subjects: 21
Study 16488056 — intervention group
Group type: COMPARATOR
Intervention: Variety condition (different sweet and salty snacks)
Number of subjects: 21
Study 14504877 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2)) 0.05 mg/day for the first 14 days, followed by 0.05 mg/day E(2) plus 0.25 mg/day norethisterone acetate (NETA) for another 14 days, for a total of 48 weeks.
Number of subjects: 748
Study 14504877 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-symptomatic women)
Number of subjects: 748
Study 11098747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 29
Study 11098747 — intervention group
Group type: COMPARATOR
Intervention: Two-tunnel technique
Number of subjects: 29
Study 11098747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute instability group
Number of subjects: 29
Study 11098747 — intervention group
Group type: COMPARATOR
Intervention: Chronic instability group
Number of subjects: 29
Study 8779380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5% with 1 in 200,000 adrenaline (pH = 7.2)
Number of subjects: 42
Study 8779380 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 1.5% with 1 in 200,000 adrenaline (pH = 4.2)
Number of subjects: 42
Study 1514346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 0.5% and adrenaline 1:250,000 (Group 1)
Number of subjects: 21
Study 1514346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 0.5% and adrenaline 1:250,000 (Group 2)
Number of subjects: 21
Study 1514346 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain prilocaine 0.5% (Group 3)
Number of subjects: 21
Study 6390999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 50
Study 6390999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50